Access Program Information
This is an active treatment, extended access study open solely to those subjects who have
successfully completed the Core and Repeat Dosing portions of the MT-3724_NHL_001_US
clinical study and who, in the investigator’s judgment, (i) have not had progressive disease
while on MT-3724 treatment (i.e.; have shown a complete or partial response or stable
disease), (ii) have experienced no clinical or laboratory toxicities that would
contraindicate further MT-3724 dosing and (iii) have no acceptable and better alternative
treatment available to them.